The asymptomatic phase of infection with human immunodeficiency virus type 1 (HIV-1) is dominated by macrophage-tropic non-syncytium-inducing (NSI) HIV-1 variants that use CD4 and chemokine receptor CCR5 for entry in their target cells [1] [2] [3] [4] [5] . In 50% of HIV-1-infected individuals, disease progression is associated with the emergence of syncytium-inducing (SI) HIV-1
variants [6, 7] , which at least use the chemokine receptor CXCR4 in addition to CD4 as entry receptor [6, [8] [9] [10] . SI conversion is followed by a more rapid decrease in CD4 cell counts and an accelerated progression to AIDS [6, 10, 11] . Naive CD4 ϩ T cells express high levels of CXCR4 and low levels of CCR5 and are targets for SI HIV-1 in vivo [12, 13] . Infection and death of naive CD4 ϩ T cells may directly interfere with T cell renewal and maintenance of the T cell pool [12] . In addition, CXCR4, in comparison with CCR5, is more broadly expressed on memory T cells [14, 15] , which provides SI HIV-1 variants with a much larger target cell population than that of R5/NSI HIV variants. A rapid loss of memory and naive CXCR4 ϩ CD4 ϩ T cells in various cell systems in vitro has been observed after inoculation with X4/SI HIV-1 but not with R5/NSI HIV-1 [16] [17] [18] . However, the majority of individuals who never develop infection with X4/SI HIV-1 variants do progress to AIDS, some of them even rapidly [6, 19, 20] . We previously demonstrated that NSI HIV-1 variants isolated from individuals with a progressive disease course are more rapidly replicating in vitro and are associated with a higher virus load in vivo, compared with NSI HIV-1 from asymptomatic individuals [20] .
In the present study, we analyzed, in a system of phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs), the in vitro cytopathic properties of R5/NSI HIV-1 variants that were obtained early and late in infection from long-term asymptomatic individuals (LTAs) and from individuals with a progressive disease course ("progressors").
MATERIALS AND METHODS

Cells and viruses.
PBMCs from buffy coats of 10 healthy blood donors selected for the absence of the CCR5D32 allele were isolated using ficoll-hypaque density centrifugation. ) in the absence of antiretroviral therapy. Of the 7 progressors, 4 (ACH 53, 172, 424, and 638) progressed very rapidly to AIDS (AIDS diagnosis at 25-76 months after seroconversion), 2 (ACH 38 and 142) were classified as typical progressors (AIDS diagnosis at 99-109 months after seroconversion), and 1 (ACH 617) was classified as a slow progressor (AIDS diagnosis at 136 months after seroconversion after 10-year period with stable CD4 ϩ T cell counts).
From each individual, 3 virus isolates were obtained at 2 different time points: at a relatively early time point in the course of infection (mean, 21 and 18 months after seroconversion for LTAs and progressors, respectively) and at a relatively late time point in the course of HIV-1 infection. For LTAs, this time point was as late as possible (mean, 113 months after seroconversion), and for progressors, the late time point was close to AIDS diagnosis (mean, 75 months after seroconversion).
Virus isolates were randomly picked and only passaged on primary PBMCs with a maximum of 4 passages/virus. Virus isolates were screened previously for coreceptor use with the U87 astroglioma cell lines stable transfected with CD4 and CCR3, CXCR4 or CCR5, and PBMCs homozygous for CCR5 D32 [21] . SI phenotype was determined by coculture of infected PBMCs with the MT2 cell line [22] .
Virus stocks were grown on PBMCs, which were cultured for 2-3 days in Iscove's modified Dulbecco's medium (IMDM) supplemented with 1 mg/mL PHA, 10% fetal calf serum (FCS), and 100 U/mL penicillin and 100 mg/mL streptomycin (P/S) before inoculation. After inoculation, PBMCs were cultured in the same medium without PHA but with 20 U/mL recombinant interleukin-2 (rIL-2; Proleukin; Chiron Benelux BV). Cell-free supernatant with HIV was preserved at Ϫ70ЊC. For mock infections, we collected and pooled the supernatant of uninfected PBMC cultures. Determination of virus titers in stock preparations (TCID 50 ) was performed on PHA-stimulated PBMCs, which were depleted for CD8 cells using the magnetic cell sorter (MACS) system (Miltenyi Biotec), according to the manufacturer's instructions. In brief, stimulated cells were washed in MACS buffer (PBS supplemented with 2 mM EDTA and 0.5% bovine serum albumin [BSA] ) and were incubated with microbeads labeled with CD8-directed antibodies, at 4ЊC for 15 min at a concentration of 20 mL/10 7 cells. Thereafter, cells were run over a LSϩ separation column attached to a MidiMACS magnet (Miltenyi Biotec). The fraction depleted for CD8 ϩ cells was collected, washed once in IMDM, and resuspended to a cell concentration of 10 6 cells/mL in IMDM supplemented with 20 U/mL rIL-2, 5 mg/mL polybrene, 10% FCS, and P/S. Titer of the stocks (TCID 50 ) was determined on CD8-depleted PBMCs from the same cell pool as the one used for further experiments. Replication kinetics and cytopathicity. Inoculation of CD8-depleted PHA-stimulated peripheral blood lym- 6 6 ϫ 10 phocytes with 2500 TCID 50 of each virus clone was performed in a 15-mL tube in a total volume of 1 mL for 2.5 h at 37ЊC. Cells were subsequently washed with IMDM and were cultured in 25-mL culture flasks at 37ЊC in rIL-2-supplemented medium for 14 days. At several time points, cells were harvested and washed for fluorescence-activated cell sorter analysis. CD4 ϩ lymphocytes were gated on the basis of their forward and side scatter and by cell-surface expression of CD4 and CD3. Cytopathicity was determined by comparing gated CD4 ϩ lymphocytes as the percentage of total cells in the HIV-1-inoculated culture, relative to the gated CD4 ϩ lymphocytes as the percentage of total cells in the mock-infected control culture [17] . At several time points, culture supernatant was harvested for analysis of p24 production by an in-house p24 antigen capture ELISA. Statistical analyses. The data used for statistical analyses were obtained at day 7 after inoculation (by that time, all the viruses had replicated substantially, and no plateau was reached for cell killing). All statistical analyses were performed with nonparametric tests, using SPSS version 10.0. The Mann-Whitney U test was used for comparison of unpaired samples. For comparison of longitudinal paired samples, the Wilcoxon-signed rank test was used. Spearman's correlation coefficient (r s ) was used for determination of correlations between studied parameters. Correlation between R5 human immunodeficiency virus (HIV) cytotoxicity and virus production in vitro. Correlations were calculated for R5 viruses isolated early and late in the course of infection from long-term asymptomatic individuals (LTAs) and individuals with a progressive disease course ("progressors"). Spearman's rank correlation coefficient (r s ) with P value is shown. Level of cytotoxicity was calculated as the percentage of viable cells in the infected culture relative to the uninfected control culture. Virus production is given as the amount of p24 gag antigen in the supernatant of the same culture, as measured in a p24 antigen capture ELISA.
RESULTS
Virus production in vitro in PHA-stimulated PBMCs by R5
HIV-1 biological clones correlates with cytotoxicity. PHAstimulated PBMCs were cell-free inoculated with HIV-1 biological clones that were isolated at relatively early and late time points in the course of infection from 14 HIV-infected individuals who never developed infection with X4/SI HIV-1 variants. Seven individuals were classified as LTAs, which was defined as 19 ; late time point, ). P p .195 P p .389 Identical results were obtained in 2 independent experiments (data not shown). The kinetics of virus replication, analyzed as cumulative p24 antigen production in the supernatant over time, were, on average almost similar for virus isolates obtained from LTAs and progressors at early and late time points (data not shown).
Increased replication capacity and cytopathicity of latestage virus isolates. We performed a pairwise analysis of the cumulative virus production at day 7 after inoculation for earlyand late-stage virus isolates that were obtained from the same individual. This pairwise analysis revealed a significant increase in virus production between viruses from early and late time points ( ; data not shown). This increase was not ob-P p .01 served in a separate analysis of early-and late-stage virus isolates from LTAs. In contrast, early-and late-stage virus isolates from progressors were significantly different in cumulative virus production at day 7 (
). This confirms previous obser-P p .028 vations that the replicative capacity of HIV-1 increases with a progressive clinical course of HIV infection [20] .
A similar profile was seen when we compared cytopathicity over time. Although an increase in overall cytopathicity was observed in a pairwise comparison of early-and late-stage viruses from LTAs and progressors (data not shown), separate analysis of the LTA virus isolates revealed no differences in cytopathicity of early-and late-stage virus isolates (figure 2A). Virus isolates obtained from progressors late in infection showed a statistically increased cytopathicity, compared with the related virus isolates obtained early infection, in pairwise analysis (
; figure 2B ). In conclusion, our findings sug-P p .018 gest that increased cytopathicity of HIV may be correlated with a progressive disease course.
DISCUSSION
HIV isolates obtained during the late stages in the course of progressive HIV-1 infection replicate more efficiently in tissue culture than isolates that are obtained during the earlier stages [20, 23] . This has been best documented for X4/SI HIV-1 variants, which emerge in 50% of HIV-infected individuals. In the present study, we demonstrated that R5/NSI-restricted HIV-1 clones obtained from patients with AIDS who had never developed infection with X4/SI virus variants are more cytopathic in vitro in PHA-stimulated PBMCs, compared with pre-AIDS R5/NSI HIV-1 clones or R5/NSI isolates obtained from LTAs.
The development of increased pathogenicity of HIV during the course of natural infection has long been known [8, 24] . It has been previously suggested that cytopathicity of primary HIV isolates may solely depend on the coreceptor usage of the virus and not on the patient's clinical status at the moment of virus isolation [25] . The differences in CD4 ϩ T cell depletion in vitro after R5/NSI infection or X4/SI infection could indeed be attributed to the capacity of X4 HIV to infect more target cells [16, 17, 25] . Naive T cells express CXCR4 but not CCR5 and, consequently, are targets for X4/SI infection [12, 13] . X4/SI HIV infection of naive T cells is considered to directly interfere with T cell renewal [12] , and, after the emergence of X4/SI HIV variants, a dramatic acceleration in CD4 cell loss in vivo can indeed be observed [6, 10, 26] . However, within the R5/NSI HIV-infected population, differences in cytopathicity can be expected and appear to not be related to differences in coreceptor usage [21] . Transmission of an R5 SIV isolate that was isolated early in infection to a new rhesus macaque resulted in a relatively mild clinical course of infection in the recipient. In contrast, transmission of an R5 SIV isolate that was obtained relatively late in infection resulted in rapid disease progression in the recipient animal, indeed pointing to increasing viral pathogenicity in the course of infection [27, 28] .
We previously demonstrated that, with progression of disease, the in vitro replicative capacity of R5 HIV-1 variants increased and that this increase correlated with increased virus load in vivo [1, 20, 29] . In our present study, we found no significant correlation between virus production level in vitro and RNA virus load in vivo (data not shown). We could demonstrate a correlation between virus production levels and cytotoxicity in vitro. Although the level of cytotoxicity did not correlate with CD4 cell loss in vivo (data not shown), our in vitro data point to a virus-mediated cell killing that also could be relevant in vivo. In the course of R5 HIV infection, CD4 ϩ T cell loss is relatively constant [6] . This indicates that the increased replicative capacity and the coinciding increased cytopathicity of R5 HIV-1 in the course of infection have much less dramatic effect on CD4 ϩ T cell loss than does cytopathicity induced by X4 HIV-1. Similarly, in our in vitro system of PHAstimulated PBMCs, the differences between early-and lateisolated virus in their capacity to induce CD4 ϩ cell killing were much more subtle than the differences in cytopathicity seen between X4 and R5 HIV-1 variants in general (data not shown). Furthermore, in collaborative studies with Scoggins et al. [30] , we also observed that, in Thy/Liv SCID-hu mouse system, latestage R5 isolates were more cytopathic than were R5 HIV biological clones obtained during early asymptomatic infection, but, in this system, late-stage R5 HIV-1 variants were never as cytopathic as X4 HIV-1 variants [31] . The underlying mechanism for the increased cytopathicity of AIDS-associated R5 HIV-1 variants remains to be established. An increased replicative capacity may simply increase the turnover rate of infected target cells. Whether this increased replication capacity is due to enhanced affinity for CD4 or CCR5, or whether other mechanisms are involved, requires further study.
